Biotech Stock Crumbles To Three-Year Low On Delayed Seizure Drug

Biotech Stock Crumbles To Three-Year Low On Delayed Seizure Drug

Shares of Zogenix crumbled to a three-year low Thursday after the biotech company announced a delay for its seizure medicine, Fintepla. The FDA will now review the drug on June 25.